Canada: The Québec Court Of Appeal Orders The Minister Of Health To Put Remicade Back On The List

Last Updated: February 26 2019
Article by Julie Desrosiers and Patricia Hénault

The highest court in Québec recently rendered its decision in Janssen inc v. Ministre de la Santé et des Services sociaux,1 reversing the Superior Court judgment and ordering the Minister of Health to reinstate Remicade on the list of drugs approved for reimbursement under Québec's public drug plan.

The Court of Appeal quashed the Minister's decision to remove Remicade from the reimbursed drug list, breaking with usual practice by the courts to defer to ministerial decisions. The Court's main basis for reversing the decision was that the Minister had not followed the principles of procedural fairness in his relations with Janssen.

Fasken (Julie Desrosiers, Christian Leblanc, Marie Lafleur and Patricia Hénault) represented Janssen in this landmark case.

Background

Every province maintains and updates a list of drugs that are covered by the basic prescription drug insurance plan and for which reimbursement is provided by the province. If a drug is not on a provincial list, it is not reimbursed, and accordingly it is less likely to be prescribed.

In Québec, according to the Act respecting Prescription Drug Insurance of Québec ('the Act'), the Minister of Health is responsible for establishing, maintaining, and updating the List of drugs that are reimbursed by the Québec public drug plan ('the List'). This List is regularly updated by Regulation according to section 60 of the Act.

Remicade is a breakthrough drug that has been marketed by Janssen for over 20 years. It is particularly effective for patients with certain chronic inflammatory diseases, including rheumatoid arthritis and Crohn's disease.

Remicade is approved by Health Canada and is prescribed Canada-wide. It is on numerous provincial reimbursement lists and had been on the Québec List since 2000.

In February 2017, the Minister of Health decided to remove Remicade from the Québec List, without consulting or advising Janssen and without providing any reasons for his decision. The Minister issued a notice on the RAMQ's website informing the public that Remicade would no longer be reimbursed for new patients.

Janssen successfully challenged this decision before the Québec Court of Appeal.

Administrative decision or regulatory decision?

A key issue in the case was whether the Minister's delisting decision was administrative or legislative in nature. Indeed, since the List is updated by regulation, does the decision to list or delist a drug amount to a Regulation? According to the Court of Appeal, the characterization has practical importance because, "issues of procedural fairness and reasonableness of the decision both hinge on that qualification."2

The Superior Court found that the Minister's decision was legislative in nature. The judgment thus set a questionable precedent: it allowed the Minister to make decisions with a substantial impact on both the patients being treated with the drug and the drug's manufacturer while holding the government to a lower standard of procedural fairness and reasonableness obligations.

The Court of Appeal explained that a legislative instrument like a statute or regulation is general and impersonal.3 It is normally directed to an indeterminate number of persons, and therefore [translation] "should not, in principle, apply specifically to individuals or individual situations."4 While exceptionally there are some regulations that apply only to one person due to factual circumstances, they are nonetheless written in general, normative terms.5

In the context of the List of drugs approved for reimbursement, even though the List is updated by regulation, that periodic update can be distinguished from "the Minister's individual decisions regarding the [specific] medications listed or removed" from the List.6 Those individual decisions are made prior to the update, "one by one, on a case-by-case basis, according to each medication in question".7

The Court of Appeal therefore held that the Minister's decision was fundamentally an administrative decision. This in turn determined the framework within which the Minister must exercise his powers, both in terms of reasonableness and procedural fairness.

Procedural fairness

The Court of Appeal concluded that the Minister's decision to remove Remicade from the List of drugs approved for reimbursement in Québec was an administrative decision and that, as a result, the Minister had to respect the rules of procedural fairness.

After examining the applicable criteria established by the Supreme Court in the well-known Baker decision,8 the Court of Appeal concluded that the Minister had an obligation to:

  1. Give Janssen sufficient notice that he intended to remove its medication from the List of drugs approved for reimbursement in Québec;
  2. Give Janssen an opportunity to make submissions relating to the decision; and
  3. Give reasons for its decision. 9

The Court of Appeal concluded that, in spite of the great deference that the courts must show for ministerial decisions,10 the Minister had not met its procedural fairness obligations.

In the instance, Janssen had not received notice that Remicade was going to be removed from the list;11 it had not been invited to a meeting with the Minister in order to disclose the reasons for the delisting and he did not give Janssen a chance to respond.12 Moreover, the Minister did not provide any reasons for his decision.13 The Court of Appeal therefore allowed the appeal, set aside the Minister's decision, and ordered that Remicade be reintroduced on the List of drugs approved for reimbursement in Québec.

Was the Minister's decision reasonable?

Having concluded that procedural fairness had not been respected, and having set the Minister's decision aside on that ground alone, the Court of Appeal did not rule as to the reasonableness of the decision. That question therefore remains open for future debate.

Lessons learned

The decision in Janssen is reassuring, since it reaffirms the basic duty of procedural fairness that is owed to everyone who is subject to administrative action or who otherwise interacts with a ministry or government entity.

This decision reminds government bodies that they are bound by the rules of procedural fairness in the actions they take and the decisions they make.

More specifically, in the context of delisting decisions from public drug plans:

  1. A party must be informed of the decision that the government intends to make;
  2. It must have the opportunity to present its position and submit its arguments; and
  3. In the event that the government nonetheless decides to make an unfavourable decision, sufficient reasons must be provided to support that decision.

Footnotes

1 Janssen inc v. Ministre de la Santé et des Services sociaux, 2019 QCCA 39 [Janssen].

2 Janssen, supra note 1 at para. 34 [translation].

3 Janssen, supra note 1 at para. 49.

4 Janssen, supra note 1 at paras. 39-40.

5 Janssen, supra note 1 at para. 50.

6 Janssen, supra note 1 at para. 45 [translation]. This is the case not only for the decision at issue (i.e. to remove Remicade from the list), but also for a series of other decisions that may be made concerning drugs that are or are not added to the list, the manufacturers of the drugs, etc. (see paras. 46-48).

7 Janssen, supra note 1 at para. 44 [translation].

8 Janssen, supra note 1 at paras. 79-80.

9 Janssen, supra note 1, at para. 81.

10 Janssen, supra note 1 at para. 80.

11 Janssen, supra note 1 at paras. 84-85.

12 Janssen, supra note 1 at para. 84.

13 Janssen, supra note 1 at para. 83.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions